Interestingly, Bruno et al. identified two phenotypes of TIL-Bs in non-small-cell lung cancer (NSCLC) as CD20+CD69+CD27+CD21+ activated TIL-Bs and CD20+CD69+CD27-CD21- exhausted TIL-Bs, which were related to an effector T cell phenotype (CD4+IFNγ+) or a regulatory T cell (Treg) phenotype (CD4+FoxP3+), respectively (33). Here, CD4 is linked to non-small cell lung carcinoma.